Cart
sales@molnova.com
Evolocumab
CAS No. 1256937-27-5
Evolocumab( —— )
Catalog No. M22151 CAS No. 1256937-27-5
Evolocumab is a human IgG2 monoclonal antibody that binds to human PCSK9 Proprotein Convertase Subtilisin Kexin Type 9).
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 851 | In Stock |
|
| 10MG | 1152 | In Stock |
|
| 25MG | 1782 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameEvolocumab
-
NoteResearch use only, not for human use.
-
Brief DescriptionEvolocumab is a human IgG2 monoclonal antibody that binds to human PCSK9 Proprotein Convertase Subtilisin Kexin Type 9).
-
DescriptionEvolocumab is a human IgG2 monoclonal antibody that binds to human PCSK9 Proprotein Convertase Subtilisin Kexin Type 9).
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetPCSK9
-
RecptorPCSK9
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1256937-27-5
-
Formula Weight144 kDa
-
Molecular Formula——
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Sreeneeranj Kasichayanula, et al. Clinical Pharmacokinetics and Pharmacodynamics of Evolocumab, a PCSK9 Inhibitor. Clin Pharmacokinet. 2018; 57(7): 769–779.
molnova catalog
related products
-
Evolocumab
Evolocumab is a human IgG2 monoclonal antibody that binds to human PCSK9 Proprotein Convertase Subtilisin Kexin Type 9).
-
Alirocumab
Alirocumab is a human monoclonal antibody that inhibits PCSK9. It is produced by recombinant DNA technology in Chinese hamster ovary cell suspension culture.
-
O-304
O-304 is a small molecule AMPK activator and PCSK9 modulator, reduces extracellular and secreted PCSK9 levels in human liver cells and reduces PCSK9 plasma levels and total cholesterol levels in obese rats.
